Keybank National Association Revance Therapeutics, Inc. Transaction History

Keybank National Association

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	BUY	$24.7 - $37.61 $9,657 - $14,705	391 Added 3.1%	13,021 $329,000
Q1 2023 May 10, 2023	SELL	$18.36 - $35.27 $44,064 - $84,648	-2,400 Reduced 15.97%	12,630 $406,000
Q4 2022 Jan 31, 2023	BUY	$18.32 - $30.66 $105,156 - $175,988	5,740 Added 61.79%	15,030 $277,000
Q3 2022 Oct 27, 2022	SELL	$14.33 - $28.47 $52,046 - $103,403	-3,632 Reduced 28.11%	9,290 $251,000
Q2 2022 Aug 08, 2022	BUY	$11.52 - $20.4 $148,861 - $263,608	12,922 New	12,922 $179,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

Stay updated on Keybank National Association with notifications on news.